title: Perspectives on Safety and Efficacy-The BOLD Phase 2 Extension Study of Siponimod in Relapsing-Remitting Multiple Sclerosis.
authors.affiliation: Medical Evidence and Observational Research Center, AstraZeneca, Gaithersburg, Maryland.
authors.forename: Edward R
authors.initials: ER
authors.lastname: Hammond
mesh_terms: D001384:Azetidines; D001593:Benzyl Compounds; D006801:Humans; D009103:Multiple Sclerosis; D020529:Multiple Sclerosis, Relapsing-Remitting
chemical_list: D001384:Azetidines; D001593:Benzyl Compounds; C578989:siponimod